Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Healthcare Sector Analysis

UpdatedAug 06, 2026
DataAggregated Company Financials
Companies1396
  • 7D-0.3%
  • 3M12.5%
  • 1Y27.7%
  • YTD6.5%

Over the last 7 days, the Healthcare industry has dropped 2.0%, driven by declines in Eli Lilly and AbbVie of 3.3% and 6.5%, respectively. In contrast, Amgen has gained 5.2%. In the past year, the industry has gained 25%. Earnings are forecast to grow by 19% annually.

Sector Valuation and Performance

Has the U.S. Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Thu, 06 Aug 2026US$6.9tUS$3.4tUS$113.6b25.9x60.7x2x
Sat, 04 Jul 2026US$7.0tUS$3.3tUS$122.0b25.8x57.4x2.1x
Mon, 01 Jun 2026US$6.4tUS$3.3tUS$122.4b23.2x52.2x1.9x
Wed, 29 Apr 2026US$6.1tUS$3.3tUS$122.0b23.3x50.2x1.9x
Fri, 27 Mar 2026US$6.1tUS$3.3tUS$126.1b22.4x48.7x1.9x
Sun, 22 Feb 2026US$6.6tUS$3.3tUS$128.1b26.6x51.1x2x
Tue, 20 Jan 2026US$6.5tUS$3.2tUS$136.3b27.3x48x2x
Thu, 18 Dec 2025US$6.4tUS$3.2tUS$135.3b26.1x47.5x2x
Sat, 15 Nov 2025US$6.3tUS$3.2tUS$134.2b26.2x46.7x2x
Mon, 13 Oct 2025US$5.9tUS$3.1tUS$137.9b24.5x42.9x1.9x
Wed, 10 Sep 2025US$5.8tUS$3.1tUS$137.6b22.9x42x1.9x
Fri, 08 Aug 2025US$5.4tUS$3.1tUS$135.6b23.2x39.7x1.7x
Sun, 06 Jul 2025US$5.6tUS$3.0tUS$127.9b24.3x43.4x1.8x
Tue, 03 Jun 2025US$5.4tUS$3.0tUS$127.2b23.6x42.4x1.8x
Thu, 01 May 2025US$5.4tUS$2.7tUS$116.9b25.5x46.6x2x
Sat, 29 Mar 2025US$5.7tUS$2.6tUS$81.5b26x69.7x2.1x
Mon, 24 Feb 2025US$5.8tUS$2.6tUS$80.5b26.6x72.4x2.2x
Wed, 22 Jan 2025US$5.9tUS$2.9tUS$78.9b28.4x74.2x2x
Fri, 20 Dec 2024US$5.7tUS$2.9tUS$78.2b27.4x73.2x2x
Sun, 17 Nov 2024US$5.9tUS$2.9tUS$76.6b27.6x77.4x2x
Tue, 15 Oct 2024US$6.2tUS$2.8tUS$60.0b29.8x104x2.2x
Thu, 12 Sep 2024US$6.3tUS$2.8tUS$60.5b29.9x103.5x2.2x
Sat, 10 Aug 2024US$6.0tUS$2.8tUS$55.0b30.4x108.8x2.1x
Mon, 08 Jul 2024US$6.1tUS$2.8tUS$62.2b30.2x98.5x2.2x
Wed, 05 Jun 2024US$6.1tUS$2.8tUS$64.1b30.3x95.9x2.2x
Fri, 03 May 2024US$6.0tUS$2.8tUS$67.3b31.4x89.6x2.1x
Sun, 31 Mar 2024US$6.3tUS$2.8tUS$83.9b32.9x75.5x2.3x
Tue, 27 Feb 2024US$6.3tUS$2.8tUS$85.5b30.9x73.9x2.3x
Thu, 25 Jan 2024US$6.4tUS$2.8tUS$91.5b31.9x69.4x2.2x
Sat, 23 Dec 2023US$6.2tUS$2.8tUS$91.6b32.6x67.4x2.2x
Mon, 20 Nov 2023US$5.8tUS$2.8tUS$90.7b27.8x63.6x2x
Wed, 18 Oct 2023US$5.9tUS$2.8tUS$98.9b26.2x59.8x2.1x
Fri, 15 Sep 2023US$6.0tUS$2.8tUS$98.6b28.9x61.3x2.2x
Sun, 13 Aug 2023US$6.2tUS$2.8tUS$99.1b28.6x62.6x2.2x
Price to Earnings Ratio

62.6x


Total Market Cap: US$6.2tTotal Earnings: US$99.1bTotal Revenue: US$2.8tTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Healthcare Sector Price to Earnings3Y Average 65.5x202420252026
Current Industry PE
  • Investors are pessimistic on the American Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 56.9x which is lower than its 3-year average PE of 65.5x.
  • The industry is trading close to its 3-year average PS ratio of 2.1x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have grown 7.0% per year over the last three years.
  • Revenues for these companies have grown 6.4% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare sector?

US Market5.51%
Healthcare-0.33%
Biotech2.65%
Healthtech1.22%
Life Sciences1.03%
Medical Equipment0.26%
Healthcare Services-1.85%
Pharma-1.93%
Industry PE
  • Investors are most optimistic about the Life Sciences industry even though it's trading below its 3-year average PE ratio of 55.8x.
    • Analysts are expecting annual earnings growth of 17.7%, which is higher than its past year's earnings growth of 8.5% per year.
Forecasted Growth
  • Analysts are most optimistic on the Biotech industry, expecting annual earnings growth of 24% over the next 5 years.
  • However this is lower than its past earnings growth rate of 64% per year.
  • In contrast, the Medical Equipment industry is expected to see its earnings grow by 17% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
AMGN AmgenUS$407.835.2%
+US$11.3b		43.3%PE25.2x
ISRG Intuitive SurgicalUS$375.206.3%
+US$7.8b		-20.9%PE42.2x
REGN Regeneron PharmaceuticalsUS$768.5810.5%
+US$6.0b		38.5%PE17.7x
PFE PfizerUS$25.812.6%
+US$3.8b		7.9%PE33.9x
RVMD Revolution MedicinesUS$197.309.1%
+US$3.5b		438.0%PB28x

Latest News

GH
US$163.18
Guardant Health
7D
13.3%
1Y
266.0%
MRK
US$128.33
Merck
7D
-1.6%
1Y
61.5%
LLY
US$1,169.86
Eli Lilly
7D
-3.3%
1Y
56.7%
CVS
US$99.12
CVS Health
7D
-6.4%
1Y
56.0%
AMGN
US$407.83
Amgen
7D
5.2%
1Y
43.3%
ABBV
US$246.20
AbbVie
7D
-6.5%
1Y
25.4%
JNJ
US$257.59
Johnson & Johnson
7D
-3.0%
1Y
51.0%
PFE
US$25.81
Pfizer
7D
2.6%
1Y
7.9%
CI
US$270.50
Cigna Group
7D
-8.8%
1Y
0.2%
ISRG
US$375.20
Intuitive Surgical
7D
6.3%
1Y
-20.9%
Narrative Update • Aug 04

ISRG: Slowing U.S. Procedures And ACA Risks Will Pressure Rich Expectations

The updated analyst price target for Intuitive Surgical moves from about $412 to $324. This reflects lower implied revenue growth and P/E assumptions, even as analysts highlight healthy procedure trends, strong profitability, and ongoing questions around U.S. procedure momentum, automation driven adoption, and Affordable Care Act related procedure risks.
REGN
US$768.58
Regeneron Pharmaceuticals
7D
10.5%
1Y
38.5%
ALNY
US$228.72
Alnylam Pharmaceuticals
7D
11.3%
1Y
-47.4%
SYK
US$337.03
Stryker
7D
-4.3%
1Y
-10.1%
ELV
US$391.24
Elevance Health
7D
4.1%
1Y
41.6%
RVMD
US$197.30
Revolution Medicines
7D
9.1%
1Y
438.0%
UNH
US$412.75
UnitedHealth Group
7D
-1.9%
1Y
67.9%
Narrative Update • Jul 28

UNH: Medicare Reset And AI Efficiency Gains Will Drive Multi Year Margin Recovery

UnitedHealth Group's updated analyst price target framework, which lifts fair value from $424.23 to $475.23, reflects analysts' refreshed models after a stronger Q2, improved visibility on Medicare and Optum Health margin recovery, as well as modestly higher assumptions for revenue growth, profit margins, and target P/E multiples. Analyst Commentary Recent research on UnitedHealth Group clusters around a more constructive view of the company following its Q2 update, while still flagging a few areas that could matter for valuation and execution.